Connect Biopharma Appoints James Zuie-chin Huang to its Board of Directors
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, has appointed James Zuie-chin Huang, M.B.A., to its Board of Directors. Huang, the Founder and Managing Partner of Panacea Venture and a significant shareholder of Connect Biopharma, brings over 30 years of biotech experience to the role.
“We are thrilled to welcome James to Connect’s Board of Directors,” said Wubin (Bill) Pan, Ph.D., M.B.A., Co-Founder, President, and Chairman of the Board of Connect Biopharma. “His breadth of biotech and investment experience will provide our Board with a unique perspective. We look forward to leveraging his deep industry insights.”
Huang expressed enthusiasm for his appointment, particularly in light of recent positive developments for the company’s lead product candidate, rademikibart, in atopic dermatitis and asthma. “I look forward to working with my fellow board members and Connect Biopharma’s leadership to advance rademikibart’s development and the broader pipeline of highly differentiated therapeutic candidates,” he commented.
Connect Biopharma focuses on developing therapies for chronic inflammatory diseases through T cell-driven research. Its lead product candidate, rademikibart, targets interleukin-4 receptor alpha for the treatment of atopic dermatitis and asthma. Other candidates in development include icanbelimod for ulcerative colitis and CBP-174 for pruritus associated with atopic dermatitis.
Huang’s career includes senior roles at Kleiner Perkins China, Vivo Ventures, Anesiva, Tularik Inc., GlaxoSmithKline LLC, Bristol-Myers Squibb, and ALZA Corp. He holds an M.B.A. from Stanford Graduate School of Business and a B.S. in chemical engineering from the University of California, Berkeley.
Analyst comment
Positive news. James Huang’s appointment to the Board of Directors brings extensive biotech experience and industry insights. Recent positive developments for the lead product candidate suggest potential growth. Market may view this as a positive development for Connect Biopharma.
